Safety And Efficacy Of First-line Epirubicin–docetaxel (ED) Versus Epirubicin–cyclophosphamide (EC): A Multicenter Randomized Phase III Trial In Metastatic Breast Cancer (MBC)

J.-U. Blohmer, M. Hauschild, J. Hilfrich, A. Kleine-Tebbe, S. Kuemmel, W. Lichtenegger

Save to my Library

Download PDF

Analyze on Scholarcy